Spots Global Cancer Trial Database for pyrotinib
Every month we try and update this database with for pyrotinib cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Pyrotinib in Combination With Neoadjuvant Chemotherapy in HR+/HER2-, HER4 High Expression Breast Cancer Patients: A Phase II Trial | NCT04872985 | Breast Cancer Hormone-recepto... | Pyrotinib Epirubicin Doxorubicin Hyd... Cyclophosphamid... Docetaxel Nab paclitaxel Placebo | 18 Years - 75 Years | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | |
| Real World Study of Pyrotinib in Human Epidermal Growth Factor Receptor-2 (HER2) Positive Breast Cancer | NCT04158505 | HER2-positive B... | non-interventio... | 18 Years - | ChineseAMS | |
| Pyrotinib Plus Vinorelbine in HER2+ Metastatic Breast Cancer Patients | NCT04517305 | Breast Cancer | 18 Years - | Fudan University | ||
| Inetetamab in Combination With Pyrotinib in HER2 Mutant or Amplified Advanced Non-small Cell Lung Cancer | NCT05016544 | Non-small Cell ... | inetetamab Pytotinib | 18 Years - | Sun Yat-sen University | |
| Pyrotinib Combined With Capecitabine in HER-2 Positive Advanced Breast Cancer and Brain Metastases (Post-PERMEATE) | NCT05359120 | Breast Cancer | - | Henan Cancer Hospital | ||
| A Prospective, Open, Multicenter Single-arm Clinical Studie of Docetaxel, Carboplatin Combined With Inetetamab and Pyrotinib in the Treatment of Local-advanced HER2-positive Breast Cancer | NCT06234137 | Breast Neoplasm... | Docetaxel Carboplatin Inetetamab Pyrotinib | 18 Years - 75 Years | First Affiliated Hospital of Wenzhou Medical University | |
| A Study of Pyrotinib Plus Vinorelbine in Comparison With Treatment of Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer | NCT03997539 | Metastatic Brea... | Pyrotinib Treatment of ph... vinorelbine | 18 Years - 70 Years | Sun Yat-sen University | |
| Treatment With Pyrotinib-Based Therapy in Lapatinib Resistant HER2-Positive Metastatic Breast Cancer | NCT04899128 | Breast Cancer | Pyrotinib | 18 Years - 70 Years | The First Affiliated Hospital with Nanjing Medical University | |
| Disitamab Vedotin + Pyrotinib Versus THP in the First-line Treatment for HER2+ Advanced Breast Cancer Clinical Trial | NCT06278870 | HER2-positive M... First-line Trea... | disitamab vedot... Pyrotinib trastuzumab Pertuzumab taxane drug | 18 Years - 75 Years | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | |
| A Study of Pyrotinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer | NCT02973737 | HER2 Positive M... | pyrotinib placebo Capecitabine | 18 Years - 75 Years | Jiangsu HengRui Medicine Co., Ltd. | |
| Pyrotinib Plus Vinorelbine Versus Lapatinib Plus Capecitabine | NCT04850625 | Breast Cancer | 18 Years - | Fudan University | ||
| The Efficacy and Safety of Pyrotinib, Trastuzumab Combined With Taxanes in the Treatment of Trastuzumab-treated HER2+ Advanced Breast Cancer (ABC). | NCT06217185 | HER2-positive B... Advanced Breast... | Pyrotinib Trastuzumab Taxanes Capecitabine | 18 Years - 70 Years | Hebei Medical University Fourth Hospital | |
| Study of Pyrotinib in Patients With Human Epidermalgrowth Factor Receptor 2 (HER2) Positive Advanced Breast Cancer | NCT01937689 | Breast Cancer | Pyrotinib | 18 Years - 70 Years | Jiangsu HengRui Medicine Co., Ltd. | |
| Pyrotinib Plus Vinorelbine Versus Lapatinib Plus Capecitabine | NCT04850625 | Breast Cancer | 18 Years - | Fudan University | ||
| Exploratory Study of Molecular Profile-Associated Evidence Guided Precision Therapy for Salivary Gland Cancer（MAPS） | NCT05087706 | Salivary Gland ... | Pyrotinib Bicalutamide Leuprorelin | 18 Years - | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | |
| Study to Evaluate SHR6390 Combined With Pyrotinib in Patients With HER2 Positive Gastric Cancer | NCT03480256 | Gastric Cancer | SHR6390 | 18 Years - 75 Years | Peking University | |
| Molecularly Targeted Umbrella Study in Luminal Advanced Breast Cancer | NCT04355858 | Breast Cancer Metastatic Canc... | SHR7390 Famitinib SHR3162 Pyrotinib Capecitabine SHR1210 Everolimus Nab paclitaxel SHR2554 SHR3680 SHR6390 SHR1701 SERD AI VEGFi | 18 Years - 75 Years | Fudan University | |
| Continuous or Intermittent Extension of Adjuvant Pyrotinib for Invasive HER2-positive Breast Cancer | NCT05910398 | Breast Cancer I... | pyrotinib | 18 Years - 70 Years | RenJi Hospital | |
| Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer | NCT04681911 | Breast Cancer | Inetetamab Pyrotinib Capecitabine Gemcitabine Vinorelbine Carboplatin Albumin paclita... Eribulin | 18 Years - 70 Years | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | |
| Neoadjuvant Study of Pyrotinib in Combination With Trastuzumab in Patients With HER2 Positive Breast Cancer | NCT03588091 | HER2-positive B... | Pyrotinib Placebo Oral Ta... Trastuzumab Docetaxel | 18 Years - 75 Years | Jiangsu HengRui Medicine Co., Ltd. | |
| Phase II Clinical Study of Pyrotinib in First-line Treatment of Primary HER2-amplified/Mutated Advanced Non-small Cell Lung Cancer | NCT05751018 | Non-small Cell ... | Pyrotinib | 18 Years - | Peking Union Medical College Hospital | |
| Single-arm, Multi-center Clinical Study of Pyrotinib Maleate Tablets Combined With Albumin-bound Paclitaxel and Trastuzumab in Neoadjuvant Treatment of Her2-positive Early or Locally Advanced Breast Cancer | NCT04917900 | Breast Cancer | Pyrotinib combi... | 18 Years - 70 Years | West China Hospital | |
| Neoadjuvant With Trastuzumab, Pyrotinib Plus Palbociclib and Fulvestrant in HER2-positive, ER-positive Breast Cancer | NCT05076695 | Estrogen Recept... HER2-positive B... | Palbociclib trastuzumab pyrotinib fulvestrant | 18 Years - | Fudan University | |
| A Clinica Study of Pyrotinib in Patients of Advanced Non-Small Cell Lung Cancer With HER2 Mutation | NCT02834936 | Non Small Cell ... | pyrotinib | 18 Years - 75 Years | Jiangsu HengRui Medicine Co., Ltd. | |
| Pyrotinib After Trastuzumab-based Adjuvant Therapy in Patients With HER2-positive Breast Cancer | NCT05880927 | Breast Cancer | Pyrotinib | 18 Years - 75 Years | Taizhou Hospital | |
| A Study of Pyrotinib Plus Vinorelbine in Comparison With Treatment of Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer | NCT03997539 | Metastatic Brea... | Pyrotinib Treatment of ph... vinorelbine | 18 Years - 70 Years | Sun Yat-sen University | |
| Pyrotinib Plus Vinorelbine in Participants With HER2-positive Previously Treated Locally Advanced or Metastatic Breast Cancer | NCT04605575 | Breast Cancer Pyrotinib Breast Diseases Vinorelbine HER2-positive B... | Pyrotinib 320mg... Pyrotinib 400mg... Pyrotinib plus ... | 18 Years - 70 Years | Sun Yat-sen University | |
| Inetetamab Plus Rapamycin and Chemotherapy for HER2+ Metastatic Breast Cancer With Abnormal Activation of PAM Pathway | NCT04736589 | Breast Cancer | Inetetamab Rapamycin Pyrotinib Chemotherapy | 18 Years - 85 Years | Peking Union Medical College | |
| Real-world Study of Pyrotinib in Neoadjuvant Therapy for HER2-positive Breast Cancer | NCT05561686 | HER2-positive B... | Pyrotinib | 18 Years - 65 Years | Hunan Cancer Hospital | |
| Phase 2 Study of Pyrotinib in Previously Treated Patients With NSCLC Having EGFR or ERBB2 Exon 20 Insertion Mutation | NCT04063462 | Non Small Cell ... | Pyrotinib | 18 Years - 80 Years | Tianjin Medical University Cancer Institute and Hospital | |
| Pyrotinib as Neoadjuvant Agent for Non-objective Response HER2-positive Early Breast Cancer | NCT04717531 | Breast Cancer | Pyrotinib Trastuzumab Pertuzumab Docetaxel Epirubicin Cyclophosphamid... | 18 Years - 70 Years | The First Affiliated Hospital with Nanjing Medical University | |
| A Study of RC48-ADC Combined With Pyrotinib For Treatment of Local Advanced or Metastasis NSCLC With HER2 Mutation | NCT05745740 | Non-small Cell ... | RC48-ADC Pyrotinib | 18 Years - 80 Years | RemeGen Co., Ltd. | |
| Study of SHR-A1811 in HER2-expression Advanced Breast Cancer With Brain Metastases | NCT05769010 | Metastatic Brea... | SHR-A1811 Pyrotinib Bevacizumab | 18 Years - 75 Years | Henan Cancer Hospital | |
| Pyrotinib Plus Trastuzumab Versus Pertuzumab Plus Trastuzumab | NCT05572645 | Breast Cancer | Pyrotinib Plus ... Pertuzumab Plus... | 18 Years - | Fudan University | |
| Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy | NCT05582499 | Breast Neoplasm Breast Cancer Breast Tumors Triple-Negative... HER2-positive B... HER2-negative B... Hormone Recepto... Hormone Recepto... Early-stage Bre... Locally Advance... | Dalpiciclib Pyrotinib SHR-A1811 SHR-1316 Camrelizumab Trophoblast cel... Pertuzumab Trastuzumab Goserelin Letrozole Nab paclitaxel Carboplatin Epirubicin Cyclophosphamid... Fluzoparib HER2 ADC | 18 Years - 70 Years | Fudan University | |
| Pyrotinib Combined With Trastuzumab, Dalpiciclib, Letrozole Versus TCbHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HR +/HER2 + Breast Cancer | NCT05638594 | Breast Cancer | Pyrotinib Trastuzumab Dalpiciclib Letrozole Pertuzumab Docetaxel Carboplatin Gonadotropin-re... | 18 Years - 75 Years | Shengjing Hospital | |
| Pyrotinib in Combination With Trastuzumab in Treatment-refractory, HER2-positive Metastatic Colorectal Cancar. | NCT03843749 | Colorectal Canc... | Pyrotinib | 18 Years - 75 Years | Shanghai Changzheng Hospital | |
| Molecularly Targeted Umbrella Study in Luminal Advanced Breast Cancer | NCT04355858 | Breast Cancer Metastatic Canc... | SHR7390 Famitinib SHR3162 Pyrotinib Capecitabine SHR1210 Everolimus Nab paclitaxel SHR2554 SHR3680 SHR6390 SHR1701 SERD AI VEGFi | 18 Years - 75 Years | Fudan University | |
| The Basket Study of Pyrotinib Maleate for HER2-Postive Solid Tumor | NCT04179656 | Solid Tumor HER2 Gene Mutat... HER-2 Gene Ampl... HER-2 Protein O... | Pyrotinib | 18 Years - 75 Years | Tianjin Medical University Second Hospital | |
| Pyrotinib Combined With Capecitabine and Bevacizumab for Patients With HER2 Positive Breast Cancer and Brain Metastases | NCT06152822 | Breast Cancer W... | pyrotinib+capec... | 18 Years - | Tongji Hospital | |
| Camrelizumab Plus Pyrotinib Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma | NCT05111444 | Gastric Neoplas... Gastroesophagea... | Camrelizumab Pyrotinib Capecitabine Oxaliplatin Paclitaxel S-1 | 18 Years - 75 Years | Fudan University | |
| A Study of Evaluating The Effects Of Pyrotinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer | NCT03980054 | Breast Cancer | Pyrotinib Placebo | 18 Years - 75 Years | Jiangsu HengRui Medicine Co., Ltd. | |
| A Study of RC48-ADC Combined With Pyrotinib For Treatment of Local Advanced or Metastasis NSCLC With HER2 Mutation | NCT05745740 | Non-small Cell ... | RC48-ADC Pyrotinib | 18 Years - 80 Years | RemeGen Co., Ltd. | |
| Molecularly Targeted Umbrella Study in Luminal Advanced Breast Cancer | NCT04355858 | Breast Cancer Metastatic Canc... | SHR7390 Famitinib SHR3162 Pyrotinib Capecitabine SHR1210 Everolimus Nab paclitaxel SHR2554 SHR3680 SHR6390 SHR1701 SERD AI VEGFi | 18 Years - 75 Years | Fudan University | |
| Trastuzumab Combined With Pertuzumab for Adjuvant Treatment of Breast Cancer After Neoadjuvant Therapy | NCT04973319 | Breast Cancer | Pyrotinib Trastuzumab | 18 Years - 75 Years | Shengjing Hospital | |
| Pyrotinib Plus Thalidomide in Advanced NSCLC Patients Harboring HER2 Exon 20 Insertions | NCT04382300 | Non-small-cell ... | pyrotinib combi... | 18 Years - 80 Years | Shanghai Chest Hospital | |
| Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer | NCT04066790 | Breast Cancer | Pyrotinib nab-Paclitaxel Trastuzumab EC chemotherapy Surgery | 18 Years - 75 Years | Shanghai Jiao Tong University School of Medicine | |
| Dalpiciclib Plus Fulvestrant With Pyrotinib in Hormone Receptor-positive, HER2-low Advanced Breast Cancer That Progressed on Previous CDK4/6i Plus AI Therapy | NCT05806671 | Breast Cancer | Dalpiciclib Pyrotinib Fulvestrant | 18 Years - | Tianjin Medical University Cancer Institute and Hospital | |
| Efficacy and Safety of Pyrotinib Maleate Combined With ARX788 Neoadjuvant Treatment in Breast Cancer Patients | NCT04983121 | Breast Neoplasm... | Next-generation... | 18 Years - 75 Years | Shengjing Hospital | |
| Inetetamab in Combination With Pyrotinib in HER2 Mutant or Amplified Advanced Non-small Cell Lung Cancer | NCT05016544 | Non-small Cell ... | inetetamab Pytotinib | 18 Years - | Sun Yat-sen University | |
| Study of Pyrotinib in Patients With Human Epidermalgrowth Factor Receptor 2 (HER2) Positive Advanced Breast Cancer | NCT01937689 | Breast Cancer | Pyrotinib | 18 Years - 70 Years | Jiangsu HengRui Medicine Co., Ltd. | |
| Pyrotinib Combined With Trastuzumab Plus Aromatase Inhibitor in Treatment of Breast Cancer | NCT04088110 | Breast Cancer F... HER2-positive B... Hormone Recepto... Metastatic Brea... Breast Diseases Hormone Recepto... | Pyrotinib Trastuzumab Aromatase Inhib... | 18 Years - 70 Years | Fuzhou General Hospital | |
| Efficacy and Safety of Pyrotinib in Patients With HER2 Mutation Advanced Non-Small Cell Lung Cancer | NCT02535507 | Non-small Cell ... | Pyrotinib | 18 Years - 80 Years | Tongji University | |
| Camrelizumab Plus Pyrotinib Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma | NCT05111444 | Gastric Neoplas... Gastroesophagea... | Camrelizumab Pyrotinib Capecitabine Oxaliplatin Paclitaxel S-1 | 18 Years - 75 Years | Fudan University | |
| RC48 Combined With EGFR or HER2 TKI for Locally Advanced or Metastatic NSCLC Patients With HER2 Alterations | NCT06185400 | Non Small Cell ... ERBB2 Mutation-... ERBB2 Gene Dupl... Disitamab Vedot... | Disitamab Vedot... third-generatio... pyrotinib | 18 Years - | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | |
| Neoadjuvant With Trastuzumab, Pyrotinib Plus Palbociclib and Fulvestrant in HER2-positive, ER-positive Breast Cancer | NCT05076695 | Estrogen Recept... HER2-positive B... | Palbociclib trastuzumab pyrotinib fulvestrant | 18 Years - | Fudan University | |
| Pyrotinib Plus Trastuzumab and Chemotherapy in HER2+ Metastatic Breast Cancer Patients | NCT05839288 | Breast Cancer | 18 Years - | Fudan University | ||
| Neoadjuvant Study of Pyrotinib in HER-2 Positive Breast Cancer | NCT04126525 | Breast Cancer F... | Pyrotinib | 18 Years - 70 Years | RenJi Hospital | |
| A Phase Ⅱ Trial of Pyrotinib Combination With CDK4/6 Inhibitor SHR6390 in Patients Prior Trastuzumab-treated Advanced HER2-Positive Breast Cancer | NCT04095390 | Metastatic Brea... HER2-positive B... | Pyrotinib SHR6390 Letrozole Capecitabine | 18 Years - 70 Years | Shandong Cancer Hospital and Institute | |
| A Study of Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+Metastatic Breast Cancer Who Have Prior Received Anthracyclin, Taxane or Trastuzumab | NCT02422199 | HER2 Positive M... | pyrotinib Lapatinib capecitabine | 18 Years - 75 Years | Jiangsu HengRui Medicine Co., Ltd. | |
| Pharmacokinetic Study of Pyrotinib and Docetaxel in Combination With Trastuzumab in Patients With HER2 Metastatic Breast Cancer | NCT04367090 | Metastatic Brea... | Docetaxel, tras... Pyrotinib | 18 Years - 75 Years | Jiangsu HengRui Medicine Co., Ltd. | |
| Neoadjuvant Study of Pyrotinib in HER-2 Positive Breast Cancer | NCT04126525 | Breast Cancer F... | Pyrotinib | 18 Years - 70 Years | RenJi Hospital | |
| Pyrotinib in Breast Cancer Patients With Poor Response to the Neoadjuvant Treatment of Trastuzumab and Pertuzumab | NCT04255056 | Breast Cancer | Pyrotinib | 18 Years - 75 Years | Sun Yat-sen University | |
| Inetetamab Combined With Pyrotinib Plus Oral Vinorelbine for the Treatment of HER2-positive Metastatic Breast Cancer | NCT05823623 | Breast Cancer | Inetetamab Pyrotinib Oral Vinorelbin... | 18 Years - 85 Years | The First Affiliated Hospital with Nanjing Medical University | |
| Exploratory Study of Molecular Profile-Associated Evidence Guided Precision Therapy for Salivary Gland Cancer（MAPS） | NCT05087706 | Salivary Gland ... | Pyrotinib Bicalutamide Leuprorelin | 18 Years - | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | |
| Phase I Study of Pyrotinib in Patients With HER2-positive Solid Tumors | NCT02500199 | Breast Cancer Gastric Cancer Solid Tumors NSCLC | Pyrotinib | 18 Years - | Hengrui Therapeutics, Inc. | |
| Pyrotinib Versus Pertuzumab in Combination With Neoadjuvant Trastuzumab and Nab-Paclitaxel in HER2+ Early or Locally Advanced Breast Cancer | NCT04900311 | HER2+ Early or ... | pyrotinib + tra... pertuzumab + tr... | 18 Years - 75 Years | Tianjin Medical University Cancer Institute and Hospital | |
| Pyrotinib in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer | NCT03412383 | Breast Cancer HER2 Gene Mutat... | Pyrotinib | 18 Years - 70 Years | Peking Union Medical College | |
| A Clinica Study of Pyrotinib in Patients of Advanced Non-Small Cell Lung Cancer With HER2 Mutation | NCT02834936 | Non Small Cell ... | pyrotinib | 18 Years - 75 Years | Jiangsu HengRui Medicine Co., Ltd. | |
| A Phase Ⅱ Trial of Pyrotinib Combination With CDK4/6 Inhibitor SHR6390 in Patients Prior Trastuzumab-treated Advanced HER2-Positive Breast Cancer | NCT04095390 | Metastatic Brea... HER2-positive B... | Pyrotinib SHR6390 Letrozole Capecitabine | 18 Years - 70 Years | Shandong Cancer Hospital and Institute | |
| Pyrotinib Versus Pertuzumab in Combination With Neoadjuvant Trastuzumab and Nab-Paclitaxel in HER2+ Early or Locally Advanced Breast Cancer | NCT04900311 | HER2+ Early or ... | pyrotinib + tra... pertuzumab + tr... | 18 Years - 75 Years | Tianjin Medical University Cancer Institute and Hospital | |
| A Study of ARX788 Combined With Pyrotinib Maleate Versus TCBHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients | NCT05426486 | HER2-positive B... | ARX788 Pyrotinib malea... Trastuzumab Pertuzumab Docetaxel Carboplatin | 18 Years - 75 Years | Shengjing Hospital | |
| Adjuvant Dual Anti-HER2 Therapy in Patients With Small, Node-negative, HER2-positive Breast Cancer | NCT04158856 | HER2-positive B... | Pyrotinib Trastuzumab | 18 Years - 70 Years | Second Affiliated Hospital, School of Medicine, Zhejiang University | |
| A Study of ARX788 Combined With Pyrotinib Maleate Versus TCBHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients | NCT05426486 | HER2-positive B... | ARX788 Pyrotinib malea... Trastuzumab Pertuzumab Docetaxel Carboplatin | 18 Years - 75 Years | Shengjing Hospital | |
| Pyrotinib Plus Vinorelbine in Participants With HER2-positive Previously Treated Locally Advanced or Metastatic Breast Cancer | NCT04605575 | Breast Cancer Pyrotinib Breast Diseases Vinorelbine HER2-positive B... | Pyrotinib 320mg... Pyrotinib 400mg... Pyrotinib plus ... | 18 Years - 70 Years | Sun Yat-sen University | |
| Pyrotinib Plus Trastuzumab After First-line TH (P) Treatment With HER-2 Positive Breast Cancer | NCT05255523 | Advanced Breast... | pyrotinib | 18 Years - 75 Years | Fujian Medical University Union Hospital | |
| Efficacy and Safety of Eribulin in the Treatment of Advanced Breast Cancer | NCT04683445 | Breast Cancer | Eribulin Trastuzumab pertuzumab Pyrotinib Pembrolizumab Camerlizumab | 18 Years - 80 Years | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | |
| Real-world Study of Pyrotinib in Neoadjuvant Therapy for HER2-positive Breast Cancer | NCT05561686 | HER2-positive B... | Pyrotinib | 18 Years - 65 Years | Hunan Cancer Hospital | |
| Pyrotinib Combined With Capecitabine Metronomic Therapy in HER2-postitive Advanced Breast Cancer | NCT03923166 | Breast Cancer | Pyrotinib capecitabine | 18 Years - 75 Years | ChineseAMS | |
| Neoadjuvant Chemotherapy With Pyrotinib, Epirubicin and Cyclophosphamide Followed by Taxanes and Trastuzumab for HER-2+ Breast Cancer | NCT04290793 | Breast Cancer | Pyrotinib Epirubicin Cyclophosphamid... Taxanes Trastuzumab | 18 Years - 65 Years | Hebei Medical University Fourth Hospital |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
